Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30302538 | 0.90 | AXL (0.48) | NPC1MAP3K11EGFRKDRFLT1 | |
| SCHEMBL22803680 | 0.90 | AXL (0.48) | NPC1MAP3K11EGFRKDRFLT1 | |
| SCHEMBL30302584 | 0.82 | NPC1 (0.55) | NPC1MAP3K11EGFRKDRFLT1 | |
| SCHEMBL22803769 | 0.82 | NPC1 (0.55) | NPC1MAP3K11EGFRKDRFLT1 | |
| SCHEMBL22803544 | 0.77 | EGFR (0.51) | NPC1MAP3K11EGFRKDRFLT1 | |
| SCHEMBL30302573 | 0.77 | EGFR (0.51) | NPC1MAP3K11EGFRKDRFLT1 | |
| SCHEMBL30625879 | 0.76 | TNIK (0.53) | NPC1EGFRKDRFLT1PRKCQ | |
| SCHEMBL22803547 | 0.76 | EGFR (0.43) | NPC1EGFRFLT1HDAC6MAPT | |
| SCHEMBL22803754 | 0.75 | IGF1R (0.49) | NPC1EGFRKDRFLT1MAPT | |
| SCHEMBL12127169 | 0.75 | MAOB (0.64) | NPC1EGFRKDRFLT1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252240-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NPC1 830/4885MAP3K11 582/4885EGFR 1391/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | NPC1 249/4885MAP3K11 935/4885EGFR 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.